Edwards Lifesciences Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Edwards Lifesciences Corporation on July 10, 2024. The filing reports a corporate governance event regarding the appointment of a new director to the Board of Directors, effective immediately.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the appointment of David T. Feinberg, M.D., to the Board of Directors. Dr. Feinberg has also been appointed to serve as a member of the Audit Committee. There are no reported changes to financial operations or strategic direction in this document.
Management Commentary and Compensation
Dr. Feinberg brings nearly three decades of experience in health system and health information technology management, including roles as Chairman of Oracle Health, former CEO of Cerner Corporation, and former President and CEO of Geisinger Health and UCLA Health. He will receive pro rata compensation for his services as a non-employee director as outlined in the Company's 2024 Proxy Statement. The Company will also enter into its standard form of indemnification agreement with Dr. Feinberg.
Key Facts for Investor Verification
- David T. Feinberg, M.D., was appointed to the Board of Directors and the Audit Committee effective July 10, 2024.
- Dr. Feinberg's compensation is based on the pro rata schedule for non-employee directors detailed in the 2024 Proxy Statement.
- The filing confirms no undisclosed arrangements or material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.
- This filing contains no financial results or guidance updates.